Merrimack Pharmaceuticals

CompanyUnited StatesFounded 2000

Merrimack Pharmaceuticals develops one asset, in phase 1 (MM-111 in her 2 gene amplification). Mostly antibody acting on ERBB2 and ERBB3; based in the United States, founded in 2000.

1
Asset
Furthest stage: Phase 1; 6
Trials: 0
Signals

Pipeline

1

MM-111
Bispecific antibody targeting ErbB2 and ErbB3 receptors to inhibit downstream oncogenic signaling.
Phase 1, Antibody, ERBB2, ERBB3, her 2 gene amplification

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials6
Similar companies6